FENNEC PHARMACEUTICALS INC.

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 Evaluable [...] Read More... from FENNEC PHARMACEUTICALS ANNOUNCES ORAL PRESENTATION OF DETAILED RESULTS FROM INVESTIGATOR-INITIATED PHASE 2 STS-J01 CLINICAL STUDY OF PEDMARK® IN JAPAN AT SIOP 2026 The post FENNEC PHARMACEUTICALS ANNOUNCES ORAL PRESENTATION OF DETAILED RESULTS FROM INVESTIGATOR-INITIATED PHASE 2 STS-J01 CLINICAL STUDY OF PEDMARK® IN JAPAN AT SIOP 2026 appeared first on Fennec Pharmaceuticals.

~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue to Validate Commercial Growth Strategy ~ ~ Real-World Evidence Presented at ASCO 2026 Reinforced that PEDMARK® Can Be [...] Read More... from Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update The post Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update appeared first on Fennec Pharmaceuticals.

Research Triangle Park, NC, June 22, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company’s [...] Read More... from FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) The post FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) appeared first on Fennec Pharmaceuticals.

Research Triangle Park, NC, June 15, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s [...] Read More... from FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) The post FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) appeared first on Fennec Pharmaceuticals.

Research Triangle Park, NC — (GlobeNewswire) –June 10, 2026 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.  Detailed [...] Read More... from FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING The post FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING appeared first on Fennec Pharmaceuticals.

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~ Research Triangle Park, [...] Read More... from FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH SUPPORTING INTEGRATION AND USE OF PEDMARK® AT THE 2026 ASCO ANNUAL MEETING The post FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH SUPPORTING INTEGRATION AND USE OF PEDMARK® AT THE 2026 ASCO ANNUAL MEETING appeared first on Fennec Pharmaceuticals.

Research Triangle Park, NC, May 18, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company’s [...] Read More... from FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) The post FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) appeared first on Fennec Pharmaceuticals.

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call [...] Read More... from FENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 14, 2026 The post FENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 14, 2026 appeared first on Fennec Pharmaceuticals.